DEVELOPMENT STAGE COMPANY Sample Clauses

DEVELOPMENT STAGE COMPANY. Aura recognizes Ontro is a development stage company, that it has an accumulated deficit and a working capital deficit, has not generated any revenue from operations and is not expected to generate any revenue from operations for some time and perhaps for years, and that proposed development expenditures are expected to result in substantial and increasing losses over at least the next several years, and possibly much longer. Investment in Ontro involves substantial risk, and Aura should not acquire the Warrants unless it can afford the complete loss of its investment. Aura has taken full cognizance of and understands all of the risk factors related to the receipt of the Warrants.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
DEVELOPMENT STAGE COMPANY. The Investor recognizes the Company is a development stage Company, that it has an accumulated deficit and a working capital deficit, has not generated any revenue from operations and is not expected to generate any revenue from operations for some time and perhaps for years, and that proposed development expenditures are expected to result in substantial and increasing losses over at least the next one or more years, and possibly much longer. Investment in the Company involves substantial risk, and the Investor can afford the complete loss of its investment. The Investor has taken full cognizance of and understands all of the risk factors related to the receipt of the Common Stock.
Sample 1Sample 2Sample 3See All (5)
DEVELOPMENT STAGE COMPANY. The Company is a development stage company without any operating history. There can be no assurance that the Company will be able to implement its business plan, raise sufficient capital to fund its development or achieve a level of operating revenues or income sufficient to enable the Company to continue as a going concern. It has no commercial products and its products in development require significant further research, development, testing, and regulatory clearances and are subject to the risks of failure inherent in the development of products based on new technologies. These risks include the possibilities that the Company’s technology or any or all of its product candidates will be found to be unsafe, ineffective or toxic, especially in immunosuppressed individuals, or fail to receive necessary regulatory clearances to develop or approve the products; that the product candidates, even if found to be safe and effective, will be difficult to manufacture on a large scale or uneconomical to market; that the product candidates will be stable enough for commercialization; that proprietary rights of third parties will preclude the Company from marketing products; or that third parties will market superior or equivalent products. There can be no assurance that the Company’s research and development activities will result in any commercially viable products.
Sample 1Sample 2Sample 3
DEVELOPMENT STAGE COMPANY. The undersigned recognizes Ontro is a development stage company, that it has an accumulated deficit and a working capital deficit, has not generated any revenue from operations and is not expected to generate any revenue from operations for some time and perhaps for years, and that proposed development expenditures are expected to result in substantial and increasing losses over at least the next several years, and possibly much longer. Investment in Ontro involves substantial risk, and the undersigned should not acquire the Common Stock unless he or she can afford the complete loss of their investment. The undersigned has taken full cognizance of and understands all of the risk factors related to the receipt of the Common Stock.
Sample 1
DEVELOPMENT STAGE COMPANY. The Purchaser acknowledges and understands that the Company is a development-stage company.
Sample 1Sample 2
DEVELOPMENT STAGE COMPANY. As a development stage company, the Company’s book value is dependent on its continuation as a going concern. Furthermore, the Company anticipates that it will generate an operating deficit during its initial operation. The Company intends to sub-license its portfolio products and technology to prospective customers, to commercialize the P3D technology in Europe, and to raise, or generate from operations, sufficient capital to continue as a going concern. The value of the Company’s assets would materially decrease were it to be unable to continue as a going concern.
Sample 1
DEVELOPMENT STAGE COMPANY. Stockholder understands fully that the Company is a development-stage company. There can be no assurance that the Company will generate any revenues, or if revenues are generated, that the Company can sustain revenues for any period of time or otherwise achieve or maintain profitability.
Sample 1
AutoNDA by SimpleDocs
DEVELOPMENT STAGE COMPANY. The Purchaser acknowledges and understands that the Company commenced operations in 1997.
Sample 1

Related to DEVELOPMENT STAGE COMPANY

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Development Efforts Genentech will use commercially reasonable and diligent efforts to develop C2B8, including pursuing preclinical development and clinical development of C2B8 and obtaining Regulatory Approvals therefor in all countries in the Licensed Territory, taking into account the scientific and commercial potential of C2B8, including, without limitation, each of the potential indications in the Field for C2B8. Within ninety (90) days of the Original Effective Date, Genentech agrees to provide IDEC with a written development strategy for C2B8 in the Licensed Territory indicating (i) whether Genentech will develop C2B8 alone or with a partner in Europe, (ii) the identity of its European partner (if any), and (iii) a list of clinical trials which Genentech would conduct for C2B8 approval in Europe assuming adequate quantities of C2B8 are available.

  • Development Diligence Novartis shall dedicate commercially reasonable efforts, during each [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards the next clinical Development milestone or approval milestone, as described in Sections 7.4.2 or 7.4.3, respectively. If Novartis (itself or through its Affiliates or sublicensees) fails to dedicate commercially reasonable efforts, during any [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards such next milestone, then any dispute regarding Novartis’ failure of development diligence with respect to such Profile shall be resolved in accordance with Article 13.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Development Period The Contractor may commence pre-construction activities like utility shifting, boundary wall construction or any other activity assigned to the Contractor by the Authority to enable construction of the Project Highway immediately after signing of the Agreement, to the extent that such work is ready for execution. The Parties agree that these works may be taken up and completed to the extent feasible by the Contractor, before declaration of the Appointed Date, but no claim against the Authority for delay shall survive during this period and that the undertaking of these works by the Contractor shall not count towards the Scheduled Construction Period of the project which starts counting only from the Appointed Date. No construction activity of the Project Highway shall be undertaken during the development period.

  • Development Schedule The Project shall substantially comply with the specific timetables and triggers for action set forth in Article 5 of this Agreement. The parties acknowledge that, as provided in G.S. 160A-400.25(b), the failure to meet a commencement or completion date shall not, in and of itself, constitute a material breach of this Agreement pursuant to G.S. 160A-400.27 but must be judged based upon the totality of the circumstances.

  • Synchronization, Commissioning and Commercial Operation 4.1.1 The Power Producer shall give at least thirty (30) days written notice to the SLDC and GUVNL, of the date on which it intends to synchronize the Power Project to the Grid System.

Time is Money Join Law Insider Premium to draft better contracts faster.